Literature DB >> 1463464

Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases.

S J Atkinson1, R V Ward, J J Reynolds, G Murphy.   

Abstract

The ability of normal rabbit dermal fibroblasts to degrade films of type IV collagen and gelatin when stimulated by phorbol ester was shown to be dependent on the induction, secretion and activation of 95 kDa gelatinase B and the secretion and activation of 72 kDa gelatinase A and stromelysin. Degradation was inhibited by exogenous human recombinant tissue inhibitor of metalloproteinases-1, specific antibodies to gelatinase and stromelysin and by the reactive-oxygen-metabolite inhibitor catalase. We discuss the various pathways for activation of matrix metalloproteinases in this model system and conclude that, although plasmin may play a key role in the activation of gelatinase B and stromelysin, gelatinase A is activated by a mechanism which has yet to be elucidated. The involvement of oxygen radicals in the direct activation of matrix metalloproteinases in this model is thought to be unlikely.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1463464      PMCID: PMC1132053          DOI: 10.1042/bj2880605

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Type I collagen degradation by mouse calvarial osteoblasts stimulated with 1,25-dihydroxyvitamin D-3: evidence for a plasminogen-plasmin-metalloproteinase activation cascade.

Authors:  B M Thomson; S J Atkinson; A M McGarrity; R M Hembry; J J Reynolds; M C Meikle
Journal:  Biochim Biophys Acta       Date:  1989-11-20

2.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.

Authors:  Y Okada; T Morodomi; J J Enghild; K Suzuki; A Yasui; I Nakanishi; G Salvesen; H Nagase
Journal:  Eur J Biochem       Date:  1990-12-27

3.  Tumor promoter-stimulated Mr 92,000 gelatinase secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080 tumor cells.

Authors:  U M Moll; G L Youngleib; K B Rosinski; J P Quigley
Journal:  Cancer Res       Date:  1990-10-01       Impact factor: 12.701

4.  Invasive and metastatic potential of a v-Ha-ras-transformed human bronchial epithelial cell line.

Authors:  R D Bonfil; R R Reddel; H Ura; R Reich; R Fridman; C C Harris; J P Klein-Szanto
Journal:  J Natl Cancer Inst       Date:  1989-04-19       Impact factor: 13.506

Review 5.  Proteolytic degradation of extracellular matrix in tumor invasion.

Authors:  K Tryggvason; M Höyhtyä; T Salo
Journal:  Biochim Biophys Acta       Date:  1987-11-25

6.  Activation of human neutrophil gelatinase by endogenous serine proteinases.

Authors:  M C Vissers; C C Winterbourn
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

7.  Inhibition of type I collagen film degradation by tumour cells using a specific antibody to collagenase and the specific tissue inhibitor of metalloproteinases (TIMP).

Authors:  J Gavrilovíc; J J Reynolds; G Murphy
Journal:  Cell Biol Int Rep       Date:  1985-12

8.  Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases.

Authors:  C M Overall; J Sodek
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

9.  The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1.

Authors:  R V Ward; R M Hembry; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1991-08-15       Impact factor: 3.857

10.  Endogenous activation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator.

Authors:  Z Werb; C L Mainardi; C A Vater; E D Harris
Journal:  N Engl J Med       Date:  1977-05-05       Impact factor: 91.245

View more
  10 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.

Authors:  R Mazzieri; L Masiero; L Zanetta; S Monea; M Onisto; S Garbisa; P Mignatti
Journal:  EMBO J       Date:  1997-05-01       Impact factor: 11.598

3.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

4.  The generation and characterization of mice expressing a plasmin-inactivating active site mutation.

Authors:  T Iwaki; C Malinverno; D Smith; Z Xu; Z Liang; V A Ploplis; F J Castellino
Journal:  J Thromb Haemost       Date:  2010-10       Impact factor: 5.824

5.  Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin.

Authors:  Q A Sang; M K Bodden; L J Windsor
Journal:  J Protein Chem       Date:  1996-04

6.  Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis.

Authors:  S Sasaki; H Iwata; N Ishiguro; K Obata; T Miura
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

7.  Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts.

Authors:  R V Ward; S J Atkinson; J J Reynolds; G Murphy
Journal:  Biochem J       Date:  1994-11-15       Impact factor: 3.857

8.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 9.  Nature-Derived and Synthetic Additives to poly(ɛ-Caprolactone) Nanofibrous Systems for Biomedicine; an Updated Overview.

Authors:  Shahin Homaeigohar; Aldo R Boccaccini
Journal:  Front Chem       Date:  2022-01-19       Impact factor: 5.221

10.  Biocomposite nanofiber matrices to support ECM remodeling by human dermal progenitors and enhanced wound closure.

Authors:  Fraz Anjum; Natacha A Agabalyan; Holly D Sparks; Nicole L Rosin; Michael S Kallos; Jeff Biernaskie
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.